SAT0166 GOLIMUMAB AS FIRST, SECOND OR AT LEAST THIRD BIOLOGIC AGENT IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA), PSORIATIC ARTHRITIS (PSA) OR ANKYLOSING SPONDYLITIS (AS) – POST HOC ANALYSIS OF A NON-INTERVENTIONAL STUDY IN GERMANY
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.3245
Abstract: Background Golimumab (GLM) has demonstrated efficacy in RA, PsA, and AS in several randomized clinical trials with biologic-naïve patients. Data from real world practice comparing biologic naïve and experienced patients are lacking. Objectives The aim… read more here.
Keywords: line; basdai; first second; least third ... See more keywords
Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Oncology"
DOI: 10.1159/000515280
Abstract: Introduction: This study compared clinical outcomes of 2nd- and 3rd-line regorafenib in patients with unresectable hepatocellular carcinoma. Methods: In this retrospective cohort study, 48 patients were treated with regorafenib for unresectable hepatocellular carcinoma. Thirty-five and… read more here.
Keywords: line; line regorafenib; 3rd line; 2nd 3rd ... See more keywords
A Single Center Retrospective Analysis of Daratumumab, Pomalidomide, and Dexamethasone As a Second Line Therapy for Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-137023
Abstract: Introduction: Currently, there are many 2nd-line treatment regimens for relapsed Multiple Myeloma (MM) but no standard therapy. Daratumumab, pomalidomide, and dexamethasone (DPd) is a newer 3-drug regimen approved by the FDA for treatment of multiple… read more here.
Keywords: line; group; 3rd line; research funding ... See more keywords